U.S. health authorities are endorsing a more convenient approach to cervical cancer prevention, a method that is not widely available in Canada. The Health Resources and Services Administration has released new guidelines that will eventually make it easier for women and individuals assigned female at birth to access self-testing kits for the human papilloma virus (HPV), a sexually transmitted infection that can lead to cervical cancer. This shift reflects a move away from the traditional Pap test in favor of HPV tests, which can be conducted either by a healthcare provider or by individuals.
Early detection of cervical cancer through regular screening has been linked to a 90 percent five-year survival rate. While many regions in Canada now recommend HPV screening over the Pap test for cervical cancer prevention, self-administered tests are not widely available outside of British Columbia.
The at-home HPV testing kits work similarly to rapid COVID-19 tests that can be done at home. The process involves using a swab to collect a sample from inside the vagina, without the need for a speculum like in a Pap test. The self-testing swab does not touch or scrape the cervix, reducing discomfort compared to traditional methods.
Unlike rapid COVID-19 tests, HPV screening samples need to be sent to a lab for analysis. Self-collection not only offers the convenience of testing at home at a preferred time but also encourages more people, including those who have never been tested or are infrequent testers, to undergo HPV screening. The Canadian Partnership Against Cancer reports that self-sampling leads to higher screening rates.
In terms of accuracy, Pap smears examine cervical cells for abnormalities or precancerous changes with an accuracy rate of less than 60 percent. In contrast, HPV testing looks for the virus’s DNA rather than analyzing cells and has an accuracy rate exceeding 90 percent in detecting the virus. Nearly all cervical cancer cases are caused by HPV, with specific strains responsible for over 70 percent of cases globally.
A positive HPV test does not guarantee cancer development but may necessitate further examination, potentially including a Pap test. However, there are rare cases where HPV testing may not be effective in detection.
Health Canada recommends Pap tests every three years and HPV screening every five years. The U.S. recommendations allow women and individuals assigned female at birth aged 30 to 65, with an average cervical cancer risk, the option to self-test. Private insurance companies will be mandated to cover the test costs starting Jan. 1, 2027.
The American Cancer Society estimates around 13,000 new cervical cancer cases annually in the U.S., leading to approximately 4,300 deaths each year. HPV infections are common, with 75 percent of sexually active individuals experiencing at least one HPV infection in their lifetime, often without symptoms. Vaccination against HPV strains has contributed to reduced cases, although recent evidence suggests a plateau in decline.
Cervical cancer rates in Canada decreased steadily from 1984 to 2005 but have since plateaued. Despite not being a leading cause of cancer death for Canadian females, the report emphasizes the preventable nature of the disease. Improving access to HPV testing and vaccination is seen as crucial for lowering cervical cancer rates.
